Primary Outcomes
Measure: Cmax: Maximum Observed Plasma Concentration for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: Cmax,u: Maximum Observed Unbound Plasma Concentration for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: AUCinf,u: Area Under the Unbound Plasma Concentration-time Curve From Time 0 to Infinity for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: AUClast: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: AUClast,u: Area Under the Unbound Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: Combined Molar Unbound Cmax, for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: Combined Molar Unbound AUClast, for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: Combined Molar Unbound AUCinf, for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: : Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: t1/2z: Terminal Disposition Phase Half-life for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: λz: Terminal Disposition Phase Rate Constant for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: CL/F: Apparent Clearance After Extravascular Administration for TAK-788 Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: CLu/F: Apparent Clearance for Unbound Drug After Extravascular Administration for TAK-788 Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration for TAK-788 Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: Vz,u/F: Apparent Volume of Distribution for Unbound Drug During the Terminal Disposition Phase After Extravascular Administration for TAK-788 Time: Day 1 pre-dose and at multiple time points (up to 216 hours) post-dose
Measure: Aet: Amount of Drug Excreted in Urine From Time 0 to time t for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose
Measure: fe,t: Fraction of Administered Dose Excreted in Urine From Time 0 to Time t TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose
Measure: CLR: Renal Clearance for TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 pre-dose and at multiple time points (up to 120 hours) post-dose
Secondary Outcomes
Measure: Plasma Protein Binding of TAK-788 and its Active Metabolites (AP32960 and AP32914) Time: Day 1 at multiple time points (up to 24 hours) post-dose
Measure: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) Time: Baseline up to 30 days after the last of study drug (Day 31)